Is there an oral version of Edaravone?

Edaravone (Edaravone) is a neuroprotective drug. It was originally developed by Japan's Taisho Pharmaceutical Company and has been used in some countries to treat certain neurological-related diseases, especially in patients with stroke (stroke) and spinal muscular atrophy (ALS).

Edaravone Injection has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The domestic price is relatively cheap. Please consult the local hospital pharmacy or medical insurance bureau for specific prices and reimbursement policies.

Edaravone Oral medicine has not yet been launched in China. There is only the American version of the original drug abroad, and the price is as high as 200,000.

Edaravone is a free radical scavenger that helps reduce cell damage caused by oxidative stress by reducing free radicals produced in the body. Oxidative stress is an important pathophysiological process in many neurological diseases (such as stroke, Alzheimer's disease, and Parkinson's disease), which may lead to nerve cell damage and death.

Specifically, the mechanism of action of edaravone involves inhibiting the production of oxygen free radicals and reducing oxidative stress caused by cerebral ischemia or other injuries. It may also exert neuroprotective effects by reducing inflammatory responses, improving cell membrane stability, and regulating the release of neurotransmitters.

Edaravone is usually used in the form of injection and is mainly used for the treatment of acute stroke. In some clinical trials, it has been shown to reduce neurological damage in stroke patients to a certain extent and improve patients' quality of life.